Bristol-Myers Squibb Company





Market Closed - Nyse 04:00:01 2023-12-01 pm EST Intraday chart for Bristol-Myers Squibb Company 5-day change 1st Jan Change
50.10 USD +1.46% +0.68% -30.37%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Bristol Myers Squibb Insider Bought Shares Worth $150,049, According to a Recent SEC Filing MT
US FDA investigating safety risk of CAR-T cancer therapies RE
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies MT
Sector Update: Health Care Stocks Ease Tuesday Afternoon MT
US FDA investigating safety risk of CAR-T therapies RE
Sector Update: Health Care Stocks Decline Premarket Tuesday MT
Sector Update: Health Care MT
Traders Await Economic Data as US Equity Futures Post Narrow Losses Pre-Bell MT
Avidity Biosciences Collaborates With Bristol Myers to Advance Use of AOC in Multiple Cardiac Targets MT
Bristol Myers Squibb to Take Stake in Avidity Biosciences, Expand Partnership DJ
Avidity Biosciences, Inc. Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for Up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology CI
Avidity Biosciences, Inc. announced that it expects to receive $39.999993 million in funding from Bristol-Myers Squibb Company CI
Global markets live: HP, Nordstrom, Deere, Nvidia, Broadcom...
Bristol Myers Squibb Insider Bought Shares Worth $423,385, According to a Recent SEC Filing MT
US Senate Health Committee Members Ask Johnson & Johnson, Merck, Bristol-Myers Squibb CEOs to Testify on Drug Pricing MT
Johnson & Johnson, Merck, Bristol Myers Squibb Invited to Testify to Senate Health Committee on Drug Prices MT
Pharma CEOs Asked by Senate to Testify on 'Outrageously' High Prices of Prescription Drugs on Jan. 25 MT
Bayer CEO says tougher cash outlook will be considered in overhaul RE
Nasdaq leads Wall Street's gains as Microsoft hits record high RE
US FDA to Miss Dec. 16 Deadline on Bristol-Myers Squib, 2seventy Bio Drug Application MT
Trending : Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDA DJ
European Equities Open Week on Flat Note in Monday Trading; Bayer Shares Tumble After Asundexian Trial Ends MT
Nasdaq leads Wall St higher as Microsoft hits record high RE
Global markets live: Microsoft, Meta Platforms, Blackstone, Citigroup, Nvidia...
Chart Bristol-Myers Squibb Company
More charts
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi.
-30.37% 102 B $
+59.64% 525 B $
+48.98% 454 B $
-10.34% 381 B $
-11.26% 253 B $
-17.52% 221 B $
+2.14% 202 B $
-9.09% 200 B $
-43.58% 163 B $
+3.74% 146 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Bristol-Myers Squibb Company - Nyse
  4. News Bristol-Myers Squibb Company
  5. Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $81 From $89, Buy Rating Kept
As early as today, start finding the best investment opportunities!
Optimize my profits